Tag: Bavencio
Merck KGaA: favorable follow-up data for Bavencio
(CercleFinance.com) – Merck KGaA presented on Friday follow-up data confirming the long-term positive phase III results obtained by its immunotherapy Bavencio in the treatment of advanced urothelial carcinoma. These results,…
Merck KGaA: Favorable follow-up data for Bavencio
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Next setback for Bavencio: Merck study on cancer immunotherapy failed
Another setback for Bavencio Merck study on cancer immunotherapy failed 2/8/2022, 5:01 p.m Merck only had to cope with two study flops in connection with a cancer drug last year.…